Fortive Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Fortive de 10% y 3.7% por año respectivamente. Se prevé que el BPA crezca en un 11.6% al año. Se espera que la rentabilidad financiera sea de 16.2% en 3 años.
Información clave
10.0%
Tasa de crecimiento de los beneficios
11.60%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Machinery | 16.3% |
| Tasa de crecimiento de los ingresos | 3.7% |
| Rentabilidad financiera futura | 16.24% |
| Cobertura de analistas | Good |
| Última actualización | 19 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • May 20
FTV: Buybacks And Sequential Execution Will Support Future Earnings Quality
Fortive's analyst price target has been raised by several firms in recent research, collectively edging higher by single digits in dollar terms. Analysts point to solid sequential growth and recent company execution to support slightly higher revenue growth and P/E expectations, even as profit margin assumptions are trimmed and the discount rate is nudged up.Actualización de narrativa • May 02
FTV: Sterilization Demand And Buybacks Will Support Future Earnings Quality
Fortive's analyst fair value estimate has been nudged up by $1 to $73 after analysts weighed a mix of recent price target increases and trims alongside recalibrated assumptions for growth, margins and future P/E levels. Analyst Commentary Recent Street research on Fortive shows a mix of target price trims and increases, with bullish analysts generally leaning toward higher fair value assumptions even as some recalibrate their models.
Actualización de narrativa • Apr 16
FTV: Future P E Compression Will Challenge Buyback Support At Current Levels
Fortive's analyst price targets have seen a mixed reset, with one firm trimming its view by $7 while several others lifted their targets by $4 to $9, as analysts factor in modest tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Fortive shows a mix of optimism and caution, with several firms lifting their price targets and one trimming its view by $7.Seeking Alpha • Apr 14
Fortive: Starting To Improve Its Performance
Summary Fortive has executed well post-Ralliant spin-off, delivering solid earnings and modest organic growth, supporting a fair valuation. Fortive's 2025 sales rose 2% to $4.16B, with 4Q organic growth exceeding 3%; adjusted EPS reached $2.71, up $0.30 YoY. Guidance targets 2026 adjusted EPS of $2.90–$3.00, underpinned by 2–3% organic growth, margin gains, and continued buybacks. At 19–20x forward earnings and leverage in the mid-2s, Fortive offers reasonable value, though upside is capped without stronger growth catalysts. Read the full article on Seeking AlphaActualización de narrativa • Apr 02
FTV: Fair Value View Balances Buybacks Against Execution And P E Compression Risks
Analysts have nudged their fair value estimate for Fortive higher to $52.50 from $51.10, reflecting updated views on revenue growth, margins, and future P/E assumptions following a mix of recent price target hikes and one downgrade across the Street. Analyst Commentary Recent Street research on Fortive shows a mixed but generally cautious tone, with a cluster of price target increases alongside at least one downgrade and a later price target cut.Actualización de narrativa • Mar 19
FTV: Fair Value Case Weighs Buybacks Against Execution And Multiple Compression Risks
Fortive's analyst price target has been adjusted slightly lower to $51.10. Analysts point to updated fair value estimates, refined discount rate assumptions, and refreshed views on revenue growth, margins, and future P/E multiples following a series of recent price target revisions across major firms.Actualización de narrativa • Mar 05
FTV: North American Sterilization Demand Will Support Future Earnings Quality Upside
Analysts have lifted their price targets on Fortive, supporting a move in our fair value estimate from $66.00 to $72.00. They cited updated expectations for revenue growth, profitability and a lower forward P/E multiple.
Actualización de narrativa • Feb 19
FTV: Recent Rating Shift And Buybacks Will Shape Future Return Profile
Our updated Fortive narrative reflects a higher implied price target of about $62, as analysts factor in steadier revenue growth assumptions, slightly stronger profit margins, a modestly lower discount rate, and a similar forward P/E, consistent with a series of recent price target increases across the Street. Analyst Commentary Recent Street research shows a cluster of higher Fortive price targets, alongside at least one downgrade.Actualización de narrativa • Feb 04
FTV: JPMorgan Downgrade And Buybacks Will Shape A Measured Return Profile
Analysts have trimmed their price target on Fortive to US$58.13, citing a slightly lower discount rate, modestly softer revenue expectations and a higher assumed profit margin supported by a reduced future P/E multiple. Analyst Commentary Recent commentary around the new US$58.13 price target reflects a mixed view on Fortive, with the latest JPMorgan downgrade underlining both execution opportunities and areas of concern for valuation and growth.Actualización de narrativa • Jan 21
FTV: Balanced Outlook As Healthcare Demand And Buybacks Shape Future Returns
Narrative Update The analyst price target for Fortive has shifted from approximately $56.13 to $58.13, as analysts cite recent model updates and sequential improvements in North American demand for sterilization and biomedical equipment, along with higher AHS adjusted EBITDA driven by gross profit growth and lower costs. Analyst Commentary Recent research on Fortive reflects a mix of optimism on execution and caution around upside potential, which is showing up in both price target changes and rating shifts.Actualización de narrativa • Jan 06
FTV: Fair Value View Balances Higher Demand With Margin Execution Risks
Analysts have increased their fair value estimate for Fortive from US$50.00 to US$52.00, citing refreshed models after the Q3 report and Street research that points to improved North American demand for sterilization and biomedical equipment, stronger AHS adjusted EBITDA margins, and updated price targets clustered around US$55 to US$58. Analyst Commentary Recent Street research on Fortive points to updated price targets clustered in the US$55 to US$58 range, with analysts revising their models following the Q3 report.Artículo de análisis • Dec 27
Estimating The Fair Value Of Fortive Corporation (NYSE:FTV)
Key Insights The projected fair value for Fortive is US$53.12 based on 2 Stage Free Cash Flow to Equity Current share...Actualización de narrativa • Dec 15
FTV: North American Sterilization Demand Will Support Earnings Quality And Upside Potential
Analysts have modestly raised their blended price target on Fortive to about $58 per share from roughly $55, citing improved North American demand for sterilization and biomedical equipment, stronger margins in Advanced Healthcare Solutions, and updated post earnings financial models that still reflect slightly softer long term growth and profitability assumptions. Analyst Commentary Bullish analysts are pointing to a constructive risk reward profile for Fortive, highlighting that incremental execution gains and healthier end market trends can support the recent step up in valuation.Actualización de narrativa • Oct 20
Recurring Software Trends Will Secure Resilience Amid Tariff Uncertainty
Analysts have lowered their fair value estimate for Fortive to $56.13 from $57.25. They cite a tougher outlook and more challenging revenue growth projections for the remainder of the year.Actualización de narrativa • Sep 18
Recurring Software Trends Will Secure Resilience Amid Tariff Uncertainty
Analysts have lowered Fortive's price target to $57.25 due to skepticism over the company's ability to meet guidance amid slowing growth in its strongest segment, caution around macro headwinds post-Ralliant spinoff, and minimal near-term revenue growth. Analyst Commentary Persistent skepticism regarding Fortive's ability to achieve its full-year guidance following a cautious update and lack of supportive industry data.Actualización de narrativa • Sep 03
Recurring Software Trends Will Secure Resilience Amid Tariff Uncertainty
Analysts have lowered Fortive’s target price to $60.50, citing uncertainty about achieving updated guidance following the Ralliant spin-off, ongoing topline and margin pressures, and diminished visibility post-restructuring. Analyst Commentary Bullish analysts highlight Fortive's high earnings visibility and strong recurring revenue profile (~50%+), expecting portfolio reviews and strategic focus on workflow management software and healthcare to support margin resilience.Artículo de análisis • May 30
A Look At The Intrinsic Value Of Fortive Corporation (NYSE:FTV)
Key Insights Fortive's estimated fair value is US$88.69 based on 2 Stage Free Cash Flow to Equity Fortive's US$71.07...Seeking Alpha • Mar 10
Fortive Seeing Signs Of Improvement, But Valuation Doesn't Make It An Easy Call
Summary Fortive's fourth-quarter results (and full 2024 results) showed fairly ordinary performance, with revenue and margins missing targets, and the business model didn't meaningfully outperform peers through the cycle. 2025 should be a better year, and I'd expect Fortive's businesses to recover ahead of more manufacturing and machinery-focused peers. The upcoming split of Precision Technologies into Ralliant may reduce complexity but is unlikely to significantly add or destroy value, but I can see potential strategic bidders for Tektronix. Despite cautious optimism for 2025, FTV's valuation doesn't justify a premium, given its inability to outgrow inflation and deliver superior full-cycle performance. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Fortive Corporation: Undervaluation And Stability Give It An Edge (Rating Upgrade)
Summary Fortive Corporation's product innovations and increased bookings, particularly in cloud-based solutions, support a recovery by 2025 despite macro uncertainties delaying short-term growth. The company’s strong cash flow, robust liquidity, and undervaluation compared to peers justify an upgrade to a "Buy" rating. Fortive's solid balance sheet, aggressive share repurchase policy, and stable cash flow position it well for superior medium-term returns. Read the full article on Seeking AlphaSeeking Alpha • Sep 22
Fortive: A Softer Performance Triggers A Separation
Summary Fortive is a solid conglomerate operating in three segments, focusing on intelligent operating solutions, precision technologies and healthcare solutions. After a softer performance of the precision technologies business this year, the company has announced plans to separate the business. The company trades at reasonable valuations and leverage, with a potential for higher valuation post-separation, expected to complete by Q4 2025. I recommend initiating positions in the $70s or high $60s, as the business separation may drive significant shareholder value. Read the full article on Seeking AlphaPrevisiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 4,677 | 747 | 1,096 | 1,189 | 8 |
| 12/31/2027 | 4,498 | 682 | 1,005 | 1,097 | 15 |
| 12/31/2026 | 4,338 | 621 | 967 | 1,040 | 13 |
| 4/3/2026 | 4,235 | 557 | 966 | 1,076 | N/A |
| 12/31/2025 | 4,159 | 533 | 978 | 1,083 | N/A |
| 9/26/2025 | 6,260 | 885 | 1,088 | 1,220 | N/A |
| 6/27/2025 | 6,237 | 879 | 1,386 | 1,514 | N/A |
| 3/28/2025 | 3,550 | 388 | 1,431 | 1,512 | N/A |
| 12/31/2024 | 4,081 | 483 | 1,441 | 1,527 | N/A |
| 9/27/2024 | 4,592 | 555 | 1,374 | 1,471 | N/A |
| 6/28/2024 | 5,083 | 661 | 1,306 | 1,424 | N/A |
| 3/29/2024 | 6,129 | 900 | 1,327 | 1,436 | N/A |
| 12/31/2023 | 3,914 | 408 | 1,275 | 1,354 | N/A |
| 9/29/2023 | 6,012 | 828 | 1,261 | 1,371 | N/A |
| 6/30/2023 | 5,973 | 800 | 1,185 | 1,289 | N/A |
| 3/31/2023 | 5,910 | 764 | 1,161 | 1,263 | N/A |
| 12/31/2022 | 5,826 | 755 | 1,207 | 1,303 | N/A |
| 9/30/2022 | 5,671 | 696 | 1,032 | 1,114 | N/A |
| 7/1/2022 | 5,516 | 659 | 976 | 1,046 | N/A |
| 4/1/2022 | 5,372 | 650 | 971 | 1,031 | N/A |
| 12/31/2021 | 5,255 | 580 | 911 | 961 | N/A |
| 10/1/2021 | 5,205 | 1,646 | 926 | 971 | N/A |
| 7/2/2021 | 5,064 | 1,562 | 1,143 | 1,191 | N/A |
| 4/2/2021 | 4,786 | 1,440 | 1,333 | 1,391 | N/A |
| 12/31/2020 | 4,634 | 1,383 | 1,361 | 1,437 | N/A |
| 9/25/2020 | 2,556 | -147 | 1,574 | 1,627 | N/A |
| 6/26/2020 | 3,256 | -26 | 1,455 | 1,527 | N/A |
| 3/27/2020 | 4,079 | 90 | N/A | 1,306 | N/A |
| 12/31/2019 | 4,564 | 199 | N/A | 1,271 | N/A |
| 9/27/2019 | 7,075 | 718 | N/A | 1,241 | N/A |
| 6/28/2019 | 6,816 | 724 | N/A | 1,247 | N/A |
| 3/29/2019 | 6,553 | 816 | N/A | 1,330 | N/A |
| 12/31/2018 | 3,800 | 455 | N/A | 1,344 | N/A |
| 9/28/2018 | 5,602 | 837 | N/A | 1,363 | N/A |
| 6/29/2018 | 5,686 | 909 | N/A | 1,295 | N/A |
| 3/30/2018 | 5,713 | 899 | N/A | 1,199 | N/A |
| 12/31/2017 | 5,756 | 884 | N/A | 1,176 | N/A |
| 9/29/2017 | 6,476 | 932 | N/A | 1,031 | N/A |
| 6/30/2017 | 6,359 | 891 | N/A | 1,043 | N/A |
| 3/31/2017 | 6,285 | 890 | N/A | 1,108 | N/A |
| 12/31/2016 | 5,378 | 740 | N/A | 1,137 | N/A |
| 9/30/2016 | 6,173 | 884 | N/A | 1,207 | N/A |
| 7/1/2016 | 6,130 | 854 | N/A | 1,112 | N/A |
| 4/1/2016 | 6,140 | 842 | N/A | 1,092 | N/A |
| 12/31/2015 | 6,179 | 864 | N/A | 1,009 | N/A |
| 10/2/2015 | 6,290 | 857 | N/A | 1,026 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10% al año) de FTV es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (10% al año) de FTV crezcan menos que el mercado US (16.8% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de FTV crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (3.7% al año) de FTV crezcan más despacio que el mercado de US (11.6% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 3.7% al año) de FTV crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de FTV sea baja dentro de 3 años (16.2%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 12:39 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/04/03 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Fortive Corporation está cubierta por 29 analistas. 15 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| John Eade | Argus Research Company |
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |